Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.